Philip Morris International closes last German factory due to declining demand

Jul.31
Philip Morris International closes last German factory due to declining demand
Philip Morris International closes last German factory in Dresden due to declining cigarette demand in Europe.

Key points:

·Philip Morris International (PMI) closed the last factory in Germany, the Dresden 'F6' factory, at the end of July. 

·The decision to close was due to a continuous decrease in cigarette demand in the European market, with statistics showing that only one out of every five Germans smoke regularly. 

·The factory primarily produced loose tobacco for consumers to purchase and use in homemade cigarettes.

 


 

According to exxpress on July 30, Philip Morris International (PMI) has decided to close its last production facility in Germany, the 'F6' factory in Dresden, at the end of July. This marks PMI's complete withdrawal from the production sector in Germany after closing the Berlin factory in June 2025.

 

The company confirmed this news after negotiating with the union. The factory, located in Dresden, Germany, was once an important tobacco processing plant for Philip Morris International (PMI).

 

As early as autumn 2024, Philip Morris International (PMI) announced plans to withdraw from production in Germany due to the continuous decline in demand for cigarettes in the European market. According to statistics, only one out of every five people in Germany regularly smokes, and this trend is continuing to diminish.

 

The closure of the Dresden factory this time will directly affect 274 employees. Recently, the factory mainly produced loose tobacco leaves for consumers to purchase and use to roll their own cigarettes.

 

At a factory in Berlin, Germany, approximately 100 employees are responsible for producing expanded tobacco leaf, which is used as filler material for filtered mouthpiece cigarettes.

 

According to a report by Exxpress, although Philip Morris International (PMI) withdrawing from manufacturing in Germany is now inevitable, the company's future direction remains clear: gradually moving away from traditional cigarettes and towards new alternative products. The company plans to have the majority of its revenue come from sales of non-traditional tobacco products before 2030.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Products | VAPORESSO Unveils Two New 10 mL Pod Devices for UK and US E-Commerce Channels
Products | VAPORESSO Unveils Two New 10 mL Pod Devices for UK and US E-Commerce Channels
VAPORESSO has recently launched two new open-system vaping devices. The XROS 5 Nano is the first to roll out across UK and US online channels, featuring 30W output and a touch-screen design, while the ECO NANO Plus has gone live on the brand’s official website with a 10 mL high-capacity pod and a 1400 mAh battery.
Nov.26 by 2FIRSTS.ai
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts observed on FOGER’s online retail site “FOGER VAPES” that the platform indicates restocking delays due to customs and tariff factors. Several items show limited availability or “sold out” status, with a restock alert feature offered. A previous article on the site also referenced potential tariff changes that may affect pricing.
Nov.05
JTI UK Expands Nordic Spirit Line, Launches 17mg Nicotine Pouch
JTI UK Expands Nordic Spirit Line, Launches 17mg Nicotine Pouch
JTI UK has launched Nordic Spirit’s highest-strength variant—Frosty Mint Max, delivering 17mg of nicotine per pouch—and introduced a refreshed, darker packaging design for the brand.
Oct.31 by 2FIRSTS.ai
South Korean Parliament advances revision of tobacco law to include synthetic nicotine products, expected to generate $6.3 billion in tax revenue
South Korean Parliament advances revision of tobacco law to include synthetic nicotine products, expected to generate $6.3 billion in tax revenue
South Korean Parliament advances tobacco law revision, including synthetic nicotine products, anticipating $630 million tax revenue increase.
Oct.16 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21
FDA CTP Acting Director  Supports Expanding Authorized Flavored E-Cigs and Legal Marketplace
FDA CTP Acting Director Supports Expanding Authorized Flavored E-Cigs and Legal Marketplace
At the FDLI Tobacco and Nicotine Policy Conference, FDA CTP Acting Director Bret Koplow spoke in favor of promoting tobacco harm reduction to reduce smoking. He backed a legal marketplace for authorized reduced-risk products, potential expansion of flavored e-cigs, and faster FDA reviews to ensure a strong, regulated market.
Oct.29 by 2FIRSTS.ai